Cancer is a complex and heterogeneous disease. It is crucial to identify the key driver genes and their role in cancer mechanisms with attention to different cancer stages, types or subtypes.
Introduction
Cancer development is influenced by mutations in two distinct categories of genes, known as tumor suppressor genes (TSG) and oncogenes (OCG) . The occurrence of mutations in TSGs generally leads to increased cell proliferation, whereas mutations in OCGs could alter or increase their biological activity.
The gain-of-function of OCGs together with the loss-of-function of TSGs determine the processes that control the tumor formation and development (Hahn and Weinberg, 2002) .
The Cancer Gene Census (CGC) (Futreal et al., 2004 ) is a catalog of somatic mutations that provides a list of currently known cancer driver genes following the OCGs / TSGs definition. The CGC contains some 600 genes implicated in cancer, but more recently, the availability of different "omics" technologies from large international consortia, such as the The Cancer Genome Atlas (TCGA) and Gene Expression Omnibus (GEO) have suggested many additional genes that may be involved in cancer and have brought new challenges to the field of cancer research (Vogelstein et al., 2013) . These consortia included data of somatic mutations, gene expression, methylation and copy number alterations, along with clinical data. They share the ambitious goal of detecting crucial genes and molecular mechanisms underlying tumorigenesis in any major cancer type (Cancer Genome Atlas Research Network, 2008) .
Several methods implemented so far used mutation data to detect candidates cancer drivers (Davoli et al., 2013) , (Schroeder et al., 2014) (Schroeder et al., 2014; de Souza et al., 2014) ) but although all these methods were demonstrated as effective, it remains critical to clarify the consequences of each mutation and to link these patterns with possible underlying biological interpretation. For example, some mutations bring premature stop codon and carry out reduced dosage of mRNA transcripts. Other mutations affect protein activities through can act as either an oncogene or tumor suppressor gene in different cancer types or during cancer progression.
For instance, most of the recent studies demonstrated that DEAD-box RNA helicase 3 (DDX3) acts as an oncogenic role in breast cancer (Bol et al., 2013) , but some studies (Su et al., 2015) ( Zhao et al., 2016) also showed that its downregulation promotes metastasis in colorectal cancer indicating a potential role as TSG.
Another example of a moonlight gene is represented by MMP12, a member of the matrix-metalloproteinase (MMP) family. The MMPs cause degradation of the extracellular matrix and basement membranes, contributing to the pathogenesis of tissue destructive processes in a wide variety of diseases. It has been proposed as an oncogene in breast cancer, (Hegedüs et al., 2008) , (Shin et al., 2005) , hepatocellular carcinoma (Ng et al., 2011) , gastric carcinoma (Cheng et al., 2010) and lung adenocarcinoma. (Lv et al., 2015) . Viceversa, in colorectal cancer, overexpression of MMP-12 is associated with increased survival of the patient, presumably as a result of an inhibitory effect on angiogenesis (Nocito et al., 2008) . These data suggest that MMP-12 has a tumor suppressor role in this context.
Why is it important to know if a gene has an oncogenic role or a tumor suppressor role in a specific tumor? A careful evaluation of the functional status of a dual-role gene and the context-dependent role in response to specific treatments in different tumors might be fundamental to guide therapeutic decisions. The identification of genes with a dual role can also be used to define common genetic profiles shared by subgroups of patients who may benefit from targeted treatment strategies. For example, ERBB2 is amplified and h changing amino acid sequences. Furthermore, tumor mutation rates can be of several orders of magnitude, but it does not necessarily mean that all of the abnormal genes are also involved in the development of cancers (Lawrence et al., 2013) .
Therefore, mutations and genes must be characterized together to identify biologically relevant mutations; an integration with functional enrichment analysis is essential in the interpretation of the disease.
However, to our knowledge, no study focuses on the methods to detect genes with dual role i.e. the moonlight genes. With the term 'moonlight gene' we mean a gene that overexpressed in 20 % to 25% of breast cancer and is the target of the monoclonal antibody trastuzumab, a drug that is effective only when ERBB2 is amplified and overexpressed (Fackenthal and Olopade, 2007) .
We here propose MoonlightR as a new approach to define TSGs and OCGs based on functional enrichment analysis, inferred gene regulatory networks and upstream regulator analysis to score the importance of key biological processes that are related to cancer, such as apoptosis or cellular proliferation, with respect to the studied cancer. In addition, the Functional Enrichment Analysis (FEA) and Upstream regulator Analysis (URA), used in the Moonlight protocol, can suggest enriched biological functions for experimental validation extracting the relevant signaling pathways from differentially expressed genes.
METHOD DETAILS
The Moonlight protocol aims:
1. To identify biological processes enriched by a gene set of differentially expressed genes (DEGs) between two conditions by means of FEA; 2. To Identify the upstream regulators of those biological processes that are enriched significantly in the comparison by means of URA; 3. To identify 'driver genes' with dual role that acts as TSG or OCG in different cancer contexts (i.e., different cancer types, subtypes or stages).
Availability
The MoonlightR package is released under GPLv3 License.
MoonlightR is freely available within the Bioconductor project at http://bioconductor.org/packages/MoonlightR/.
Data preparation and analysis
The legacy level-3 data of the PanCancer studies (18 cancer types) from the The Cancer Genome Atlas (TCGA) cohort deposited in the Genomic Data Commons (GDC) Data Portal were used in this study and downloaded in May 2017.
RNA-seq raw counts of 7364 cases (6652 TP and 712NT samples) as legacy archive, and using the reference of the hg19 genome were downloaded, normalized and filtered using the R/Bioconductor package TCGAbiolinks version 2.5.9 using GDCquery(), GDCdownload() and GDCprepare() functions for tumor types (level 3, and platform "IlluminaHiSeq_RNASeqV2"), as well as using data.type as "Gene expression quantification" and file.type as "results". This allowed to pull out the raw expression signal for expression of a gene for each case following the TCGA pipeline used to create Level 3 expression data from RNA Sequence data that uses MapSplice (Wang et al., 2010) to do the alignment and RSEM to perform the quantification (Li et al., 2010) . Integrative analysis using mutation, clinical and gene expression were performed following our recent TCGA's workflow .
For the case study n.2 and n.3 we used Breast invasive carcinoma (BRCA) from TCGA as deposited in the GDC Data Portal. In particular, RNA-seq raw counts of 1211 BRCA cases as legacy archive, and using the reference of hg19 were downloaded, normalized and filtered using the R/Bioconductor package TCGAbiolinks following the above pipeline. Among BRCA samples 1097 were Primary solid Tumor (TP) and 114 solid Tissue Normal (NT). The aggregation of the two matrices (tumor and normal) for both tumor types was then normalized using within-lane normalization to adjust for GC-content effect on read counts and upper-quantile between-lane normalization for distributional differences between lanes applying the TCGAanalyze_Normalization() function adopting the EDASeq protocol (Risso et al., 2011) and (Bullard et al., 2010) .
Molecular subtypes, mutation data and clinical data were pulled using TCGAbiolinks and the following functions: TCGAquery_subtype(), GDCquery_maf() retrieving somatic variants that were called by the MuTect2 pipeline, and GDCquery_clinic() respectively.
For BRCA tumors with PAM50 classification (Ciriello et al., 2015) were stratified in 5 molecular subtypes: Basal-like (98) 
Databases
Gene Programs used for Moonlight analysis were expert-based selected considering biological functions enriched by the PanCancer comparison, using the differential expressed genes between tumor samples and normal samples.
Furthermore we used the Molecular Signatures Database (MSigDB) considering the following collections to perform the Gene Set Enrichment Analysis (GSEA) analysis. (Subramanian et al., 2005 
Gold-standard of known driver genes (OCG and TSG)
A recent review has argued that a comparative assessment of role prediction methods is not straightforward due to the lack of a clear gold-standard of known OCGs and TSGs (Tokheim et al., 2016) . To create the best currently available training set of known OCGs and TSGs we added those genes to our training set that are verified by at least two sources.
We retrieved a list of validated OCGs and TSGs from the Catalogue of somatic mutations in cancer (COSMIC) (Forbes et al., 2008 (134), dominant/recessive (7) and undeclared (3).
Crossing these two types of information shows that all OCGs are linked to dominant mutation and most TSGs are linked to recessive mutations (42), nine are linked to dominant mutations.
A second list was published in (Vogelstein et al., 2013) , it consists of 54 OCGs and 71 TSG. 
Functionalities overview
The Moonlight pipeline tool / suite provides well-known and new functionalities as illustrated in ( Figure 1 ), in particular here follows the details and each of the functions to be employed: 
G ene R egulatory N etwork ( GRN ) inferred between each single DEG (sDEG) and all
genes by means of mutual information, obtaining for each DEG a list of regulated genes (RG).
5. U pstream R egulator A nalysis ( URA ) for DEGs. In each enriched gene set, we defined a Moonlight Z-score as the ratio between the sum of all predicted effects for all the gene involved in the specific function and the square-root of the number of all genes.
6. P attern R ecognition A nalysis ( PRA ) identifies candidate TSGs (down) and OCGs (up).
We either use user defined biological processes or random forests.
7. We applied the above procedure to multiple cancer types to obtain cancer-specific lists of TCGs and OCGs. We compared the lists for each cancer: if a sDEG was TSG in a cancer and OCG in another we defined it as dual-role TSG-OCG. Otherwise if we found a sDEG defined as OCG or TSG only in one tissue we defined it tissue specific biomarker.
8. We used the COSMIC database to define a list of gold standard TSG and OCGs to assess the accuracy of the proposed methods.
ROMA score for pathway activity
For the pathway activity evaluation, Representation and quantification Of Module Activity (ROMA) (See https://github.com/sysbio-curie/Roma) (Martignetti et al., 2016) 
RESULTS
Case study n.1a (FEA using TCGA BRCA gene expression)
In this case study using we defined a gene expression signature (GeS) after running
TCGAanalyzeDEA between breast cancer samples BRCA TP and NT obtained 3390 DEGs namely the differentially expressed genes (DEGs). Figure 2 showed the top 32 BPs enriched significantly with |Moonlight-score| >=1 and FDR <= 0.01 using the above GeS. Increased levels reported in yellow and decreased in purple, and in green showing the -logFDR / 10. A negative Z-score indicates that the process' activity is decreased. A positive Z-score indicates that the process' activity is increased.
We performed Upstream regulator analysis (URA) using the GeS (n=3390 DEGs) defined in case study n.1a to identify the cause of a downstream effect in cellular biology. The identification of upstream regulator molecules and their related biological processes can help to better understand the detected expression changes by the DEA.
In the figure below ( Figure 3 ) we applied also the Pattern recognition Analysis on the URA obtained from the BRCA considering as apoptosis of tumor cell lines and proliferation of cells as the interested biological process for the definition of upstream regulators.
by ROMA-score
We computed the activity score of biological processes potentially modulated by OCG and TSG using ROMA (Representation and quantification Of Module Activities) (Martignetti et al., 2016) , a gene-set-based quantification algorithm, for more details see Methods. As a case study, we applied ROMA to the BRCA dataset of TCGA (table: module_scores.xls). This approach revealed substantial similarity with the results obtained by Moonlight Z-score.
transcriptomic heterogeneity in cancer tissue by identifying dual role genes.
In this case study, we used the expression levels of genes in all the samples obtained from TCGA / GDC with IlluminaHiSeq RNASeqV2 in 18 normal tissues (NT) and 18 cancer tissues (CT) according to the TCGA criteria ( Table 1 ). We applied the complete Moonlight pipeline (FEA-URA-PRA) to extract those genes that were significantly increasing or decreasing biological processes such as proliferation of cells and apoptosis.
( Figure 4) showed the results of the moonlight pipeline for case study n.2 that can be visualized with a circos plot using the function plotCircos. 
Conclusion
In this paper, we proposed a new methodology called Moonlight to identify driver cancer genes and their specific role in different contexts. In particular, our method can predict oncogenes (or tumor suppressor genes) as those genes that increase (decrease) biological processes related to cancer growth while at the same time decrease (increase) biological processes that are blocking cancer growth. Moreover, our approach sounds promising to identify those genes with a dual role i.e., the moonlight genes. These genes are emerging in cancer studies and they are elusive to identify due to their context-dependent role, i.e. they could act as an oncogene in a 
